Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDS00135

Target Information
NameNMDA receptor    
Type of targetSuccessful target    
DiseaseAlzheimer's disease
[ICD9: 331.0   ICD10: G30]
[1]
Amyotrophic lateral sclerosis
[ICD9: 335.20   ICD10: G12.2]
[1]
Analgesics
[ICD9: 338   ICD10: R52]
[1]
Chronic pain
[ICD9: 338.2,780   ICD10: R52.1-R52.2, G89]
[1]
Epilepsy
[ICD9: 345   ICD10: G40]
[1]
Parkinson's disease
[ICD9: 332   ICD10: F02.3, G20]
[1]
Psychosis
[ICD9: 290-299   ICD10: F20-F29]
[2]
Stroke
[ICD9: 434.91   ICD10: I61-I63]
[1]
Drug(s)AmphetamineApprovedAttention deficit hyperactivity disorder[3]
BenzphetamineApprovedObesity[3]
D-cycloserineApprovedBacterial infections[4][5]
FelbamateApprovedEpilepsy[6][7][8]
KetamineApprovedAnesthetic[9][10][11]
L-Glutamic AcidApprovedSchizophrenia[12]
Magnesium SulfateApprovedAcute pain[13]
MemantineApprovedAlzheimer's disease[14][15]
Nitrous oxideApprovedAnaesthesia[16]
OrphenadrineApprovedParkinson's disease[17][18]
Dextromethorphan+quinidinePhase III completedPainful diabetic neuropathy[19]
Amitriptyline+ketaminePhase IIINeuropathic pain[19]
DexanabinolPhase IIITraumatic brain injury[20]
MagnesiumPhase IIIAcute ischemic stroke[21]
MemantinePhase IIINeuropathic, Pain[10]
AZD6765Phase IIMajor Depressive Disorder[22]
CHF-3381Phase IINeuropathic pain[19]
CNS-5161Phase IINeuropathic pain[19]
D-cycloserinePhase IIObsessive-compulsive disorder[4][5]
D-serinePhase IISchizophrenia[23]
NeramexanePhase IICancer pain[24]
EAA-090Terminated in Phase IIPainful diabetic neuropathy[19]
RemacemideDiscontinued in Phase IParkinson's Disease[10][25]
RemacemideDiscontinued in Phase IIIHuntingtonĄ¯s disease[26][10]
ADX-2 seriesPreclinicalSchizophrenia[23]
MemantinePreclinicalParkinsonĄ¯s Disease[27][28]
BioChemical ClassIon transport    
PathwayAlzheimer's disease
Amyotrophic lateral sclerosis (ALS)
Calcium signaling pathway
Long-term potentiation
Neuroactive ligand-receptor interaction
Systemic lupus erythematosus
Related US Patent6,262,106
6,284,774
6,448,270
6,451,819
6,479,553
6,495,587
6,500,838
6,534,525
6,548,516
6,551,993
6,635,270
6,642,256
6,642,267
6,649,605
Target ValidationClick to Find Target Validation Information.    
AgonistD-cycloserine[4][5]
Remacemide[10][25]
Remacemide[26][10]
AntagonistACEA-1328[24]
ADX-2 series[23]
AZD-4282[29]
AZD6765[22]
Amitriptyline+ketamine[19]
Amphetamine[3]
Aptiganel HCl[25]
Benzphetamine[3]
C-101,606[30]
CHF-3381[19]
CNS-5161[19]
Dexanabinol[20]
Dextromethorphan+quinidine[19]
Dextrorphan[25]
EAA-090[19]
Felbamate[6][7][8]
Huperzine A[31]
Ketamine[9][10][11]
L-Glutamic Acid[12]
Magnesium[21]
Magnesium Sulfate[13]
Memantine[10]
Memantine[27][28]
Memantine[14][15]
Neramexane[24]
Nitrous oxide[16]
Orphenadrine[17][18]
Selfotel[25]
ModulatorD-serine[23]
MultitargetCHF-3381[19]
Dextromethorphan+quinidine[19]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Activators and inhibitors of the ion channel of the NMDA receptor. Curr Drug Targets. 2001 Sep;2(3):323-9. To Reference
Ref 2Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse. 2004 May;52(2):114-22. To Reference
Ref 3J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. To Reference
Ref 4How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. To Reference
Ref 5Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. To Reference
Ref 6Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. Epub 2008 Feb 27. To Reference
Ref 7Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65. Epub 2008 Feb 4. To Reference
Ref 8Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85-110. To Reference
Ref 9Ketamine Modulates Theta and Gamma Oscillations. J Cogn Neurosci. 2009 Jul 7. [Epub ahead of print] To Reference
Ref 10Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. To Reference
Ref 11Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. To Reference
Ref 12Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry. 2008 Dec;165(12):1594-603. Epub 2008 Oct 15. To Reference
Ref 13Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95. To Reference
Ref 14Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation. Neuropsychopharmacology. 2009 Jun 17. [Epub ahead of print] To Reference
Ref 15Mechanism for quinolinic Acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009 Jul;16(1):77-86. Epub 2009 Apr 18. To Reference
Ref 16Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. To Reference
Ref 17Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35. Epub 2009 Feb 12. To Reference
Ref 18Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. 1997 Jul;21(4):393-400. To Reference
Ref 19Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. To Reference
Ref 20Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. To Reference
Ref 21Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42. To Reference
Ref 22AstraZeneca. Product Development Pipeline. January 29 2009. To Reference
Ref 23The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. To Reference
Ref 24Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. To Reference
Ref 25Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. To Reference
Ref 26Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97. To Reference
Ref 27Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference
Ref 28From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. Epub 2009 Jun 5. To Reference
Ref 29Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. To Reference
Ref 30Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001 Jan;1(1):13-8. To Reference
Ref 31Epilepsy Res. 2009 Jan;83(1):1-43. Epub 2008 Nov 12.Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543